Seven Fleet Capital Management LP Buys New Stake in Definium Therapeutics, Inc. $DFTX

Seven Fleet Capital Management LP purchased a new stake in shares of Definium Therapeutics, Inc. (NASDAQ:DFTX) in the second quarter, Holdings Channel.com reports. The institutional investor purchased 148,647 shares of the company’s stock, valued at approximately $6,992,000. Definium Therapeutics comprises 1.2% of Seven Fleet Capital Management LP’s holdings, making the stock its 20th biggest holding.

Other institutional investors have also made changes to their positions in the company. Nykredit A S bought a new stake in Definium Therapeutics in the 2nd quarter valued at $45,000. Cerity Partners LLC grew its stake in shares of Definium Therapeutics by 2.4% in the 2nd quarter. Cerity Partners LLC now owns 49,650 shares of the company’s stock valued at $322,000 after purchasing an additional 1,165 shares during the period. Creative Planning lifted its holdings in shares of Definium Therapeutics by 2.6% during the second quarter. Creative Planning now owns 66,097 shares of the company’s stock valued at $429,000 after acquiring an additional 1,655 shares during the period. Russell Investments Group Ltd. lifted its holdings in Definium Therapeutics by 110.4% during the 2nd quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock valued at $25,000 after purchasing an additional 2,003 shares during the last quarter. Finally, Mercer Global Advisors Inc. ADV raised its stake in shares of Definium Therapeutics by 10.5% in the third quarter. Mercer Global Advisors Inc. ADV now owns 21,931 shares of the company’s stock valued at $259,000 after acquiring an additional 2,079 shares during the last quarter. 27.91% of the stock is currently owned by institutional investors.

Definium Therapeutics Price Performance

Shares of DFTX opened at $38.09 on Friday. The stock has a market cap of $5.12 billion, a P/E ratio of -11.10 and a beta of 2.23. Definium Therapeutics, Inc. has a 1 year low of $8.77 and a 1 year high of $49.70. The stock’s 50-day moving average price is $43.70 and its two-hundred day moving average price is $29.49. The company has a current ratio of 6.95, a quick ratio of 6.95 and a debt-to-equity ratio of 0.04.

Definium Therapeutics (NASDAQ:DFTX) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($1.44) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.89). On average, equities analysts predict that Definium Therapeutics, Inc. will post -3.02 earnings per share for the current year.

Analyst Ratings Changes

DFTX has been the subject of several research reports. JonesTrading raised their price objective on shares of Definium Therapeutics from $74.00 to $90.00 and gave the company a “buy” rating in a research report on Thursday, August 13th. Robert W. Baird upped their price objective on Definium Therapeutics from $57.00 to $75.00 and gave the stock an “outperform” rating in a report on Thursday, August 13th. Leerink Partners set a $52.00 target price on Definium Therapeutics and gave the stock an “outperform” rating in a research report on Monday, June 22nd. Needham & Company LLC raised their price target on Definium Therapeutics from $50.00 to $66.00 and gave the company a “buy” rating in a report on Wednesday, August 12th. Finally, Wall Street Zen cut Definium Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 8th. Two analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $63.00.

Insiders Place Their Bets

In other Definium Therapeutics news, insider Mark Sullivan sold 13,008 shares of the firm’s stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $45.03, for a total transaction of $585,750.24. Following the sale, the insider directly owned 320,571 shares in the company, valued at approximately $14,435,312.13. This trade represents a 3.90% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Robert Barrow sold 29,208 shares of the stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $45.03, for a total transaction of $1,315,236.24. Following the sale, the chief executive officer directly owned 1,098,246 shares of the company’s stock, valued at $49,454,017.38. This represents a 2.59% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 67,119 shares of company stock worth $2,887,496. Company insiders own 2.40% of the company’s stock.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.